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Abstract
Cancer cells are the product of genetic disorders that
alter crucial intracellular signaling pathways
associated with the regulation of cell survival,
proliferation, differentiation and death mechanisms.
The role of oncogene activation and tumor suppressor
inhibition in the onset of cancer is well established.
Traditional antitumor therapies target specific
molecules, the action/expression of which is altered
in cancer cells. However, since the physiology of
normal cells involves the same signaling pathways
that are disturbed in cancer cells, targeted therapies
have to deal with side effects and multidrug
resistance, the main causes of therapy failure. Since
the pioneering work of Otto Warburg, over 80 years
ago, the subversion of normal metabolism displayed
by cancer cells has been highlighted by many studies.
Recently, the study of tumor metabolism has received
much attention because metabolic transformation is
a crucial cancer hallmark and a direct consequence
of disturbances in the activities of oncogenes and
tumor suppressors. In this review we discuss tumor
metabolism from the molecular perspective of
oncogenes, tumor suppressors and protein signaling
pathways relevant to metabolic transformation and
tumorigenesis. We also identify the principal
unanswered questions surrounding this issue and the
attempts to relate these to their potential for future
cancer treatment. As will be made clear, tumor
metabolism is still only partly understood and the
metabolic aspects of transformation constitute a major
challenge for science. Nevertheless, cancer
metabolism can be exploited to devise novel avenues
for the rational treatment of this disease.
Introduction
Cancer arises when cells undergo uncontrolled
proliferation through enhanced activity of oncogenes and
reduced activity of tumor suppressors. Normal cells
undergo six major alterations to become tumor cells,
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namely, “self-sufficiency” in growth signals, insensitivity
to antigrowth signals, evasion of programmed cell death,
limitless replicative potential, sustained angiogenesis, and
tissue invasion and metastasis [1]. An additional alteration,
the subversion of normal cell metabolism, has recently
been identified as another important hallmark of cancer
cells [2].
Although the unique characteristics of tumor cell
metabolism have been studied since the pioneering work
of Nobel Prize winner Otto Warburg over 80 years ago
[3], the relative importance of this metabolism for tumor
onset and growth is only now gaining attention. Recent
studies have demonstrated the essential role of glucose
and glutamine in maintaining the appropriate function of
key metabolic pathways and their contribution to metabolic
transformation in cancer cells. Considering the relative
inefficiency of antitumor therapies in targeting the six
canonical hallmarks of cancer mentioned above, a better
knowledge of cancer cell metabolism would certainly
provide new possibilities for cancer treatment and an
important improvement in traditional therapeutic strategies.
In this review, we summarize the current scenario
of this new field of cancer biology, generally referred to
as the Warburg effect. In particular, we discuss the
relative contribution of glycolysis and oxidative
phosphorylation in supplying the energy requirements of
normal proliferating cells and tumor cells and the new
findings about the central role of the tricarboxylic acid
(TCA) cycle, pentose phosphate pathway and
glutaminolysis in cancer cell growth. In addition, recent
discoveries on the effects of oncogenes and tumor
suppressors in controlling specific metabolic pathways
and the overall metabolic control associated with growth
signaling pathways are reviewed.
The Warburg effect
In the 1920s, Otto Warburg published the seminal
observation that rapidly proliferating ascites tumor cells
consume glucose at a surprisingly high rate compared to
normal cells. Additionally, Warburg found that even at
normal O2 tension these cells fermented glucose into
lactate rather than oxidizing it completely, a phenomenon
known as the Warburg effect [3-5]. Since this remarkable
discovery, many reports have documented the Warburg
effect in a variety of tumors, reinforcing Warburg´s
observation that cancer cells use mainly glycolysis for
generate energy [6, 7]. The functional rate of this “aerobic
glycolysis” and lactate production correlates with
the degree of tumor malignancy, i.e., aerobic glycolysis is
faster in highly de-differentiated and fast growing
tumors than in slow-growing tumors or normal cells. In
addition, a high glycolytic rate in tumor cells has
been related to resistance to chemo- and radiotherapy
[8, 9].
One of the possible explanations for the increase in
tumor cell glycolytic rate is the overexpression of glucose
transporters (GLUT) and of virtually all enzymes of the
glycolytic pathway as a consequence of oncogene
activation [10-12]. Accordingly, the high levels of glucose
uptake in malignant cells have been associated with
increased expression of glucose transporter proteins, such
as GLUT1, GLUT3 and/or GLUT12 [11]. Furthermore,
the overexpression and/or overactivation of hexokinase
(HK), phosphofructokinase (PFK) and pyruvate kinase
(PK), the main enzymes controlling the glycolytic pathway,
has been described for a number of tumors [10, 12, 13].
Interestingly, tumor cells have been suggested to use
isoforms of glycolytic enzymes that differ from those used
to drive glycolysis in normal cells, although this issue
remains little studied and is controversial [14-20].
The distinctively higher levels of glucose uptake
displayed by tumor cells compared to other tissues have
been exploited clinically and are used to diagnose, monitor
and treat cancer. For example, with positron emission
tomography (PET), which uses 18F-deoxyglucose as a
glucose analogue and tumor marker, it is possible to detect
and gauge the size of a tumor before and after anticancer
therapy. Additionally, PET allows the tracking of
metastasis with an accuracy >90%. These findings
indicate the close relationship between the Warburg effect
and the invasiveness and metastatic potential of cancer
cells [21].
In addition to their direct clinical applications and
contribution to the study of cancer biology, Warburg’s
observations also raised some disturbing questions. For
example, considering that the metabolism of glucose to
lactate generates only two ATPs per molecule of glucose
whereas oxidative phosphorylation generates up to 36
ATPs through complete oxidation of one glucose molecule,
why do cancer cells, which have a high rate of proliferation
and, consequently, consume a large amount of ATP,
“choose” to oxidize glucose partially through aerobic
glycolysis rather than completely oxidizing this compound
through mitochondrial metabolism? And why do cancer
cells, even in the presence of sufficient oxygen, “prefer”
to obtain the ATP necessary for growth and proliferation
through a less efficient form of metabolism (in terms of
the number of ATP molecules produced)?
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One explanation for the apparent preference of
cancer cells for the glycolytic pathway was provided by
Warburg himself. His original hypothesis proposed that
cancer originated from irreversible damage to
mitochondrial respiration followed by an increase in
glycolysis to replace the ATP lost from defective oxidative
phosphorylation. This shift from oxidative phosphorylation
to glycolysis turns highly differentiated cells into
undifferentiated cells that proliferate as cancer cells [6,
22]. However, since Warburg´s original discovery, many
studies have demonstrated that in most tumors
mitochondria are not dysfunctional and that oxygen
consumption by these cells is not reduced when compared
to their non-tumor counterparts [13, 23, 24]. Additionally,
normal proliferating cells also reprogram their metabolism
to fuel the simultaneous need for growth and proliferation
through increased rates of glycolysis, even under normoxic
conditions and in the presence of functional mitochondria
(see reference 22 for an excellent review of metabolism
in normal proliferating cells). Together, these findings
demonstrate that the Warburg effect frequently develops
independently of the state of mitochondrial function and
that metabolic reprogramming is not limited to tumor cells
but, rather, is a common metabolic switch occurring in all
proliferating cells, with tumor cells having a higher level
of glycolysis compared to their normal proliferating
counterparts.
The glycolytic pathway: fuelling cellular
growth and proliferation with ATP and
macromolecular precursors
As indicated above, it is strange that the glycolytic
pathway, rather than mitochondrial metabolism, should
predominate in normal highly proliferating cells and
cancer cells, particularly in view of the relative inefficiency
of glycolysis in completely oxidizing glucose and the
large amount of energy required to drive anabolic
processes during cell growth and proliferation. However,
inefficient ATP production by glycolysis is apparently a
problem only when nutritional resources are scarce.
Recent studies of metabolic pathways and their regulation
in proliferating cells have shown that, in the presence of
abundant nutrients, anaerobic glycolysis provides cells
with high ratios of ATP/ADP and NADH/NAD+,
regardless of how much these cells are stimulated to divide
[15, 22, 25]. In addition to a large amount of ATP, growing
and proliferating cells also require a means of rapidly
producing this energy. In this regard, the high rates of
glycolysis observed in normal proliferating cells and
cancer cells provide an appropriate means of
producing ATP to meet the anabolic and bioenergetic
requirements. Indeed, when glucose is in excess, glycolysis
can potentially produce ATP in greater amounts and
faster than mitochondrial oxidative phosphorylation [22,
26, 27]. A parallel situation is observed in fermenting
yeasts which grow at higher rates than those that use
oxidation-based metabolic processes [28], indicating that
high glycolytic rates can boost cell growth and proli-
feration.
A second advantage of the high glycolytic rate in
normal proliferating cells and cancer cells is related to
the high demand for NADPH and molecular intermediates
to sustain the continuous synthesis of macromolecular
building blocks needed to drive the increase in cellular
biomass and duplication of genetic material. Cell growth
requires more equivalents of carbon and NADPH than
ATP to sustain lipid, amino acid and nucleotide
biosynthesis. Consequently, proliferation and growth can
be sustained by processes that not only produce ATP but
also generate a large amount of reducing power and
metabolic intermediates required by anabolic pathways.
In this regard, aerobic glycolysis represents an adequate
metabolic pathway for growing and proliferating cells
since, at high rates, it provides cells with ATP and glycolytic
intermediates that are an important source of precursors
for the synthesis of non-essential amino acids, lipids and
nucleic acids. In addition, the accumulation of glycolytic
intermediates can stimulate the oxidative and non-
oxidative arms of the pentose phosphate pathway to
generate, respectively, NADPH and ribose-5-phosphate
for nucleic acid biosynthesis [6]. Importantly, the increased
rate of NADPH production also provides a reducing
environment for the anabolic synthesis of biomolecules
such as fatty acids and cholesterol (Fig. 1).
The high rate of glycolysis in proliferating cells can
also help to protect against cellular oxidative damage.
The increased levels of intracellular NADPH generated
through stimulation of the pentose phosphate pathway by
glycolytic intermediates lead to an increase in the reduced
form of glutathione (GSH), a major non-enzymatic
antioxidant. Glycolysis may therefore have an important
role in maintaining the integrity and functionality of
biomolecules during the enhanced biosynthesis of
macromolecules and genetic material in proliferating cells.
The increased levels of reduced GSH may also help to
detoxify antineoplastic drugs or antagonize their effects.
Indeed, higher glycolytic rates are associated with more
aggressive and resistant tumors [21, 29].
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The functions of glycolytic enzymes are not restricted
to the glycolytic pathway since these enzymes are also
involved in non-glycolytic functions that contribute to
tumor development, survival and, importantly, resistance
to cell death. Thus, for example, hexokinase II (HK2),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
Santos de Souza/Zenker Justo/Ribeiro de Araújo/Martins Cavagis
Fig. 1. The importance of glycolysis and the TCA cycle for cancer cells. A high glycolytic rate supports tumor growth and
proliferation. In the presence of abundant glucose, the glycolytic pathway provides tumor cells with the ATP and macromolecular
precursors necessary to supply their bioenergetic and anabolic requirements. Furthermore, the high use of glucose by the
glycolytic pathway stimulates the pentose phosphate pathway, leading to an increase in ribose 5-phosphate levels and NADPH
production. Cancer cells can use ribose 5-phosphate to synthesize nucleotides required for the duplication of genetic material,
RNA synthesis and protein translation. The enhanced production of NADPH is a crucial event since this compound provides the
reducing power for macromolecule biosynthesis while at the same time protecting these macromolecules against oxidative stress.
Although the role played by the TCA cycle in energy production by cancer cells is uncertain, this cycle has an important function
as a source of molecular precursors for the synthesis of biomolecules. 1,3-BPG: 1,3-bisphosphoglycerate; 2PG: 2-phosphoglycerate;
3PG: 3-phosphoglycerate; ALA: alanine; ARG: arginine; ASN: asparagine; ASP: aspartate; CIT: citrate; CYS: cysteine; DHAP:
dihydroxyacetone phosphate; F1,6BP: fructose 1,6-bisphosphate; F6P: fructose-6-phosphate; FUM: fumarate; G3P: glyceraldehyde
3-phosphate; G6P: glucose-6-phosphate; GLN: glutamine; GLU: glutamate; GLU: glucose; GLUT: glucose transporter; GLY:
glycine; GSH: reduced form of glutathione; GSSG: oxidized form of glutathione; ICIT: isocitrate; LDH-A: lactate dehydrogenase
A; MAL: malate; ME: malic enzyme; mRNA: messenger RNA; OAA: oxaloacetate; PDC: pyruvate dehydrogenase complex; PEP:
phosphoenolpyruvate; PPP: pentose phosphate pathway; PRO: proline; PRPP: phosphoribosylpyrophosphate; PYR: pyruvate;
rRNA: ribosomal RNA; SER: serine; SUC: succinate; Suc-CoA: succinyl-CoA; tRNA: transfer RNA; TYR: tyrosine; D-KG:
D-ketoglutarate.
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and lactate dehydrogenase (LDH) have non-glycolytic
functions that confer relative advantages to cancer cells.
GAPDH and LDH are incorporated into the
transcriptional factor complex OCA-S, which increases
histone transcription (H2B gene) and favors tumor
growth. GAPDH also interacts with nucleic acids and
participates in transcriptional regulation (as a nuclear
tRNA export protein and regulator of mRNA stability)
and DNA replication and repair [30-33]. The embryonic
isoform of PK, known as pyruvate kinase M2 (PK-M2),
can translocate to the nucleus where it participates in the
phosphorylation of histone 1. PK-M2 may also modulate
transcription factors, such as Oct4, that play an important
role in preventing the expression of genes associated with
differentiation [34]. The glycolytic enzyme
phosphoglycerate kinase (PGK) is secreted by tumor cells
and acts as a disulfide reductase that facilitates the
cleavage of disulfide bonds in plasmin, thereby triggering
proteolytic release of the angiogenesis inhibitor, angiostatin
[35].
Wartenberg et al. [36] recently described an
association between high glycolytic metabolism and
increased expression of P-glycoprotein (P-gp). P-gp is a
member of the ABC (ATP binding cassette) transporters,
a family of transmembrane proteins that act as efflux
pumps and efficiently remove structurally unrelated
chemotherapeutic drugs from tumor cells, thereby
lowering the intracellular drug concentration below the
effective dose, in a phenomenon known as multidrug
resistance (MDR). MDR is currently considered the main
obstacle in effective cancer therapy since acquisition of
the MDR phenotype by cancer cells prior to or during
therapy is responsible for the failure of most antineoplastic
therapies in eradicating the disease. These findings
suggest that the inhibition of glycolysis could be used to
reverse the MDR phenotype and improve traditional
antineoplastic therapies.
High glycolytic rates confer resistance to
death
As stated above, high levels of glycolysis are
associated with increased resistance of cancer cells to
cell death, including that induced by therapeutic agents.
Hence, understanding the molecular basis of this
relationship is fundamental for improving current
antitumor therapies and for developing more effective
death-inducing drugs. Recent studies have contributed to
this goal by demonstrating that the non-enzymatic
functions of glycolytic enzymes and/or the accumulation
of key glycolytic intermediates can affect the normal
mitochondrial physiology, inducing a phenotype of
increased resistance to cell death [37-39].
One of the glycolytic enzymes whose functions
extend beyond glycolysis is HK2. This enzyme catalyzes
the first step of glycolysis and is highly expressed in
transformed cells. Curiously, in cancer cells, over 70%
of HK2 is bound to mitochondria, indicating the existence
of an alternative role for this enzyme besides its classic
function in the glycolytic pathway. In agreement with this
conclusion, Pastorino et al. [40] demonstrated that HK2
competes with Bcl2 family proteins for binding to the
voltage-dependent anion channel (VDAC) to influence
the balance of pro- and anti-apoptotic proteins that control
permeabilization of the outer mitochondrial membrane.
During apoptosis, pro-apoptotic proteins of the Bcl2
family, such as Bax and Bak, oligomerize in the outer
mitochondrial membrane to form a channel through which
cytochrome c is released. Once in the cytosol, cytochrome
c associates with other proteins to form the apoptosome,
which is responsible for the execution phase of apoptosis
by stimulating caspase activation. The binding of HK2 to
the VDAC displaces the anti-apoptotic protein Bcl-XL
and makes it available for interaction with Bax and Bak,
thereby inhibiting their pro-apoptotic actions that can
contribute to outer membrane permeabilization. The
binding of HK2 to VDAC also affects channel
permeability, leading to a closed state that inhibits
cytochrome c release. In addition, HK2 antagonizes the
pro-apoptotic effects of the protein Bid, which is
responsible for the activation of Bax and Bak [38].
The involvement of high glycolytic rates in the
resistance of cancer cells to apoptosis is also
demonstrated by the effect of glycolytic intermediates
on mitochondrial structure. Accelerated glucose
metabolism leads to a predominance of reduced
cytochrome c over its oxidized form, and reduced
cytochrome c is unable to trigger cell death despite being
released from the mitochondrial intermembrane space.
This response is strongly related to the repression of
oxidative metabolism in cancer cells exposed to high
glucose concentrations, a phenomenon known as the
Crabtree effect [41]. The precise mechanism by which
the Crabtree effect is triggered is unknown, although
several mechanisms have been proposed to explain its
function. Diaz-Ruiz et al. [37] demonstrated that the
glycolytic intermediate fructose 1,6-biphosphate inhibits
the activity of cytochrome c oxidase, leading to inhibition
of the mitochondrial respiratory chain and a decrease in
Molecular Basis of Tumor Metabolism Cell Physiol Biochem 2011;28:771-792
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respiration; this action favors the maintenance of
cytochrome c in its reduced state in which is unable to
trigger programmed cell death. This observation provides
a rational explanation for the association between
glycolysis, the Crabtree effect and apoptosis repression,
namely, that the inhibitory action of the high glycolytic
rate of tumor cells on mitochondrial respiration may serve
to protect against cell death by reducing the production
of reactive oxygen species (ROS) and inhibiting
cytochrome c-induced cell death [37].
The various aspects discussed above clearly indicate
that the resistance of cancer cells to death is strongly
related to mitochondrial structure and function. Increased
glycolytic activity and the overexpression of glycolytic
enzymes can help cancer cells avoid death induced by
anticancer drugs, either by altering the mitochondrial
structures involved in the release of cytochrome c and
apoptotic factors into the cytosol where they subsequently
trigger apoptosis, or by inhibiting ROS formation through
interference with the electron transport chain. These
mechanisms could provide a basis for the inclusion of
glycolysis-inhibiting drugs in the current arsenal of
antitumor drugs.
The advantage of lactate secretion for
cancer cells
The apparently inefficient ATP-producing glycolytic
pathway benefits highly proliferating cells by increasing
their rate of biomass formation. However, although the
glycolytic pathway does offer advantages to proliferating
cells, three carbon atoms are still lost in the form of lactate
secreted by the cells. How can this loss of oxidizable
carbons favor cancer cell growth and proliferation? An
important consideration here involves the metabolic
pathways active in specialized non-proliferating tissues
that recycle the excess lactate and alanine released by
rapidly proliferating cells [25]. Tumor cells can take
advantage of the lactate secreted by other cells in specific
situations since cellular metabolism within a tumor is
usually heterogeneous, especially in growing tumor
masses where the oxygen and nutrient supply by the blood
decreases in central regions as tumor volume increases.
An interesting “metabolic symbiosis” has been proposed
between well-oxygenated (aerobic) and poorly
oxygenated (hypoxic) cancer cells within the tumor mass.
Hypoxic cells are characterized by a large demand for
glucose uptake and a high lactate release via the
monocarboxylate transporter 1 (MCT1). Normoxic cells
can, in turn, take up the secreted lactate through other
MCTs, such as MCT4, and convert it to pyruvate, which
fuels mitochondrial metabolism. Through this mechanism,
peripheral cancer cells, which have access to major
nutrients and oxygen from blood, can meet their energy
requirements by oxidizing pyruvate derived from the
lactate secreted by hypoxic cells. This use of pyruvate
reduces the uptake of blood glucose by normoxic cells,
leading to a higher glucose concentration in the blood
reaching the hypoxic central regions of the tumor. This
greater glucose availability in turn enhances the survival
of hypoxic tumor cells, which obtain their energy
requirements for growth and survival solely through
anaerobic glycolysis [42].
The secretion of lactate by plasma membrane MCTs
(which co-transport H+ with lactate) has been related to
the maintenance of an acidic microenvironment that favors
tissue invasion and metastasis. Cancer cells can also affect
the extracellular pH by modulating the activity of the Na+-
H+ exchanger, surface V-type H+-ATPase and/or surface
F1F0 ATPase and carbonic anhydrase isoforms 9 and 12
(CA9 and CA12). The increase in extracellular acidity
may activate cathepsins and metalloproteinases, leading
to the degradation of extracellular matrix and an increase
in the susceptibility of the endothelial basal membrane to
proteolytic attack [7, 21, 43]. The ability of cancer cells
to increase the extracellular H+ concentration in a variety
of ways attests to the importance of this phenomenon in
cancer invasiveness and metastasis.
The high glycolytic pathway activity responsible for
the increased glucose consumption in cancer cells provides
a fast way of meeting at least three requirements for
rapid growth in proliferating cells, namely, an abundant
energy supply, the availability of reducing power for the
synthesis of biomolecules, and the formation of ribose-5-
phosphate for nucleotide and nucleic acid biosynthesis.
The rapid growth that accompanies the increased glucose
uptake characteristic of the Warburg effect is directly
associated not only with the high rate of glycolysis but
also with stimulation of the pentose phosphate pathway.
In agreement with this observation, certain tumor cells
may grow in culture in the absence of glucose, as long as
there are substrates to feed the pentose phosphate
pathway. In addition, the metabolic adaptations of tumor
metabolism include enhancement of the pentose phosphate
pathway and a specific balance between the oxidative
and non-oxidative branches to maintain the high
proliferative rates [44-46].
Whereas the importance of a high rate of glycolysis
in proliferating cells to meet the demands for biomass
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production and to protect newly synthesized molecules
against oxidative damage through NADPH is clear, the
real contribution of this metabolic pathway in supplying
all of the energy requirements in cancer cells is still a
matter of debate. This question is closely related to the
current discussion about the functional state of the TCA
cycle and mitochondrial oxidative phosphorylation in these
cells. Indeed, the functional roles of the TCA cycle in
these cells have been extensively debated, indicating the
need for more studies in this area.
The anabolic and catabolic functions of the
TCA cycle in cancer cells
Pyruvate: a scarce source of carbon atoms for
the TCA cycle?
Although some tumors have defective mitochondria
(as initially hypothesized by Warburg), in most tumor cells
mitochondrial function remains normal [13, 47, 48]. An
intriguing question is therefore why only about 10% of
the pyruvate generated by the glycolytic pathway actually
feeds into the TCA cycle and mitochondrial metabolism.
What are the molecular mechanisms responsible for this
observation?
Evidence for the limited delivery of pyruvate to
mitochondria comes from observations that tumor cells
selectively express PK-M2. Unlike other PK isoforms,
PK-M2 is negatively regulated by tyrosine-phosphorylated
proteins downstream from a variety of growth factor
signals. PK-M2 can exist in either dimeric or tetrameric
forms, which allows the enzyme to oscillate from the high
activity form (tetrameric) to the low activity form
(dimeric). When in its dimeric (low activity) form, the
enzyme acts as a metabolic regulator that drives the flow
of carbon into anabolic pathways, thereby avoiding its
conversion to lactate or complete catabolism in
mitochondria to generate ATP [15, 21, 49]. In tumor cells,
PK-M2 occurs predominantly as a dimer with low activity,
suggesting that its activity may be a target of oncogenes,
many of which are tyrosine kinases that regulate growth
factor signaling pathways [49, 50].
It is tempting to speculate that the low activity of
PK-M2 in cancer cells is the key adaptation of tumor
metabolism that limits the amount of pyruvate available
for mitochondrial metabolism and determines the
metabolic differences between these cells and
untransformed cells. However, this apparent obstacle to
the delivery of large amounts of pyruvate to mitochondria
could be counterbalanced by the high rates of glucose
uptake and increased glycolysis characteristic of cancer
cells. Other mechanisms (metabolic adaptations) may also
be involved in deviating pyruvate from mitochondria thus
stimulating its conversion to lactate. Two such
mechanisms include the partial block of pyruvate transport
to mitochondria and the overexpression of lactate
dehydrogenase A (LDH-A). Indeed, in some cancer cells,
the transport of pyruvate to mitochondria is slower than
in non-tumor cells [51-54]. However, the question of
whether pyruvate transport is diminished in tumor cells
and the physiological consequences of this remain
unanswered. The purification and characterization of the
mitochondrial carrier for pyruvate would greatly enhance
our limited knowledge of pyruvate transport.
In addition to a low level of pyruvate transport,
another explanation for the low rates of pyruvate oxidation
in mitochondria is the increased expression of the
glycolytic enzyme LDH-A induced by oncogenes. LDH-
A converts pyruvate to lactate, with the concomitant
oxidation of NADH to NAD+. Since NAD+ is essential
for glycolysis, the overexpression of LDH-A in tumor
cells allows NADH to be quickly oxidized to NAD+ in
the cytosol, thereby enhancing the glycolytic flux under
aerobic conditions [6]. This overexpression of LDH-A
could contribute to the rapid conversion of pyruvate into
lactate and to the diversion of most of the pyruvate
generated by PK-M2 away from mitochondria.
An alternative or additional explanation for the high
rates of glycolysis and lactate release in cancer cells is
that these events are consequences of a massive
production of pyruvate and reflect the inability of
mitochondrial pathways to oxidize pyruvate rapidly enough
to deal with the large amounts of this compound generated
by glycolysis. Curiously, the pyruvate dehydrogenase
complex (PDC), a group of enzymes responsible for the
conversion of pyruvate into acetyl-CoA, is phosphorylated
and has diminished activity in tumor cells. The action of
the PDC commits the pyruvate molecule to complete
oxidation via the TCA cycle or, alternatively, directs its
carbon atoms to be used in the de novo synthesis of
macromolecules. In normal proliferating cells, the
glycolytic flux may exceed the PDC activity by more
than one order of magnitude and, in this case, the
conversion of pyruvate to lactate could prevent the
intracellular accumulation of pyruvate and, consequently,
the triggering of death mechanisms [22]. Whether a similar
mechanism occurs in tumor cells remains to be
determined.
In summary, it seems likely that tumor cell
mitochondria are exposed to diminished amounts of
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pyruvate. Consequently, these cells meet their energy
requirements primarily through the glycolytic pathway.
Interestingly, although some tumor cells have defective
mitochondrial metabolic pathways, most of them depend
upon the delivery of pyruvate to mitochondria and on the
proper functioning of mitochondrial respiration to survive.
In agreement with this, recent work by Thangaraju et al.
[55] demonstrated the vital role of pyruvate transport to
mitochondria in preventing colon cancer cell death. Thus,
in addition to the mechanism that diverts pyruvate from
further metabolism in mitochondria and the existence of
mitochondria-defective tumors, it seems that the amount
of pyruvate that reaches the TCA cycle in cancer cells is
crucial for meeting the energy and/or anabolic
requirements of these cells. Indeed, pyruvate is the main
source of carbon atoms that, once incorporated into the
TCA cycle in the form of acetyl-CoA, drives the de novo
synthesis of lipids and proteins [56].
The TCA cycle as a source of metabolic substrates
for the synthesis of biomolecules and cellular
organelles
In order to proliferate, cancer cells need a large
amount of energy and biomolecules as building blocks.
An adequate supply of energy and biomolecules allows
the cells to maintain their physiological functions and
furnishes the anabolic pathways with ATP and substrates
necessary for proliferation. The TCA cycle is essential
for driving these events. Although the contribution of this
cycle to ATP production by supplying the electron transport
chain with reduced coenzymes is not exactly known, its
central role as a source of metabolic intermediates for
anabolic pathways (lipid, protein and nucleic acid
biosynthesis) in growing cells is well-established (Fig. 1).
The importance of the TCA cycle in proliferating cells is
further illustrated by the fact that this pathway displays
enhanced activity in a variety of tumor cells [57].
The first step in the TCA cycle is the formation of
citrate from the condensation of acetyl-CoA and
oxaloacetate, a reaction catalyzed by the enzyme citrate
synthase. The rate of the TCA cycle is strongly associated
with the relative amounts of these compounds. As
mentioned, glycolytic pyruvate is the main source of
acetyl-CoA, which is produced through catalysis by the
PDC. Since the TCA cycle activity is increased in cancer
cells it is likely that the amount of glucose-derived pyruvate
delivered to mitochondria is high enough to supply the
cycle´s requirements for acetyl-CoA. The TCA cycle has
an interesting means of obtaining the oxaloacetate required
to react with acetyl-CoA. In normal cells, increased
concentrations of acetyl-CoA are counterbalanced by the
action of pyruvate carboxylase, an enzyme whose activity
is allosterically regulated by the levels of acetyl-CoA;
high levels of this compound stimulate pyruvate
carboxylase and the conversion of pyruvate into
oxaloacetate, thereby diverting pyruvate from the PDC
and increasing the production of citrate. However,
pyruvate carboxylase is suppressed in some tumor cells
[20, 58, 59], raising questions as to how cancer cells can
obtain the oxaloacetate essential for enhanced TCA cycle
activity. The answer appears to be related to the high
demand for glutamine by cancer cells [60].
In addition to glucose, glutamine is an important
substrate for tumor cell growth and proliferation [60, 61].
The catabolism of glutamine may continuously supply the
TCA cycle with D-ketoglutarate, allowing the generation
of oxaloacetate and other metabolic intermediates
required for biosynthetic pathways. At the same time,
supplying glutamine to the TCA cycle stimulates the
activity of this pathway and enhances mitochondrial
respiration in tumor cells, in a response dependent on
increased NADH and FADH2 production [62, 63].
Furthermore, glutamine-dependent transamination can
provide nitrogen for the synthesis of non-essential amino
acids, and glutaminolysis (the conversion of glutamine into
lactate), like the metabolism of glucose via the pentose
phosphate pathway, produces NADPH via malic enzyme,
a NADP+-specific malate dehydrogenase (Fig. 2). Recent
studies suggest that the amount of NADPH supplied by
malic enzyme for cellular metabolism is the same as that
provided by the pentose phosphate pathway, further
highlighting the importance of glutamine in generating the
redox potential required for anabolic processes in cell
growth [56, 64].
Finally, the diversion of glutamine-derived malate
from pyruvate to oxaloacetate, concomitant with the
generation of acetyl-CoA from pyruvate through the
PDC, also contributes to citrate production in the first
step of the TCA cycle. These reactions initiate the
oxidation of glutamine and glucose carbons in order to
generate ATP or, alternatively, can be the starting point
for the synthesis of macromolecule precursors, such as
those associated with lipid synthesis in the cytosol. During
the synthesis of fatty acids, the carbons from glucose
and glutamine are exported from the mitochondrial
matrix to the cytosol in the form of citrate. In the cytosol,
citrate is converted to acetyl-CoA and oxaloacetate by
the action of ATP-citrate lyase (ACL) in a reaction that
requires free energy from ATP hydrolysis. The acetyl-
CoA generated is used to extend the fatty acid acyl chains
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through a series of reactions that consume NADPH as a
reducing source.
Another important issue related to the TCA cycle is
the relative extent to which tumor cells use the carbon
atoms derived from glucose and glutamine to drive the
synthesis of biomolecules or energy (in the form of ATP).
Some cancer cells show a considerable citrate
efflux from mitochondria and appear to have a “truncated”
TCA cycle feeding the production of cholesterol, fatty
acids and other products [56, 65, 66]. However, there is
also evidence for an apparently normally functioning
TCA cycle in a variety of other tumor cells that appear to
depend on mitochondrial metabolism for their
energy requirements [47, 48]. The “truncated” TCA cycle
therefore cannot be considered a general characteristic
of the Warburg effect.
Molecular Basis of Tumor Metabolism
Fig. 2. Glutamine boosts the TCA cycle function in cancer cells. Glutamine, the most abundant amino acid in the blood, supplies
the TCA cycle by generating D-ketoglutarate. The increased availability of this intermediate allows its conversion to malate,
which can be transported to the cytosol where it is converted into pyruvate and then into lactate. During this process, known as
glutaminolysis, the intermediates formed can be used to synthesize macromolecules necessary for tumor growth. In addition, the
malate produced in response to glutamine can be diverted from lactate production in the cytosol to its oxidation in subsequent
reactions of the TCA cycle, thereby contributing to the synthesis of ATP and reduced coenzymes, the latter being a stimulator of
the electron transport chain. The term “truncated” TCA cycle reflects the fact that part of the citrate produced is diverted from the
pathway to the synthesis of lipids. AA: amino acid; AA transp: amino acid transporter; Gase: glutaminase; GD: glutamate
dehydrogenase; GLUT: glucose transporter; LDH-A: lactate dehydrogenase A; MCT: monocarboxylate transporter; ME: malic
enzyme; PDC: pyruvate dehydrogenase complex; Tase: transaminase.
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The demand for glutamine in many cancer cells far
exceeds the requirement for nucleotide synthesis or
maintenance of the non-essential amino acid pool,
indicating that by using glutamine as an energy substrate
the TCA cycle can provide proliferating cells with building
blocks for proteins, nucleotides and lipids and, at the same
time, stimulate mitochondrial oxidative phosphorylation via
the increased amounts of reduced coenzymes delivered
to the electron transport chain. The importance of
glutamine as an energy substrate in cancer cells is further
illustrated by the observation that various oncogenes, such
as Myc, stimulate glutaminolysis through a transcriptional
program [67, 68].
Contribution of the TCA cycle and oxidative
phosphorylation to the energy requirements of
cancer cells
Recent studies that have focused on metabolic
pathways and their regulation in proliferating cells
suggest that the glycolytic pathway alone can account
for the ATP synthesis required to drive the biosynthetic
pathways and cell survival. Aerobic glycolysis can rapidly
produce ATP in sufficient amounts to drive anabolic
processes in proliferating cells. However, this is true
only if there is an abundant glucose source, which has
important implications for the metabolic changes that
occur in normal proliferating cells and cancer cells. In
vivo, cells are frequently exposed to fluctuations in
glucose and nutrient availability. In particular, cancer
cells face restrictions in nutrient availability (and its
subsequent metabolic implications) associated with an
increase in tumor mass. As the tumor grows, the metabolic
demands also increase, imposing an important metabolic
challenge, i.e., how to survive fluctuations in the
availability of nutrients and oxygen when tumor
growth outpaces the delivery capacity of the existing
vasculature.
Considering that normal cells proliferate only
when stimulated by growth factors whereas tumor cells
proliferate in a growth factor-independent manner, any
analysis of the energy contribution of aerobic glycolysis
to proliferating cells must take into account the normal or
transformed nature of the cells. The specific location of
a cell within the tumor mass must also be considered
since this location will influence the availability of
nutrients and oxygen and, consequently, the metabolic
adaptations occurring within each cell. Specific metabolic
adaptations can therefore occur in different populations
of cells, in agreement with the metabolic heterogeneity
of the tumor mass. This metabolic heterogeneity
influences cancer metabolism studies and is critical
to the development of anticancer therapies.
The importance of distinguishing the metabolic
adaptations that occur in normal proliferating cells
from those in tumor cells becomes even more evident
when the functional status of glycolysis and mitochondrial
oxidative phosphorylation are correlated to the
triggering of biological mechanisms (such as proliferation,
senescence and apoptosis) that control the cell´s fate.
During proliferation, cells must rapidly replicate their
genomes while simultaneously avoiding mutations in
their DNA. Normal cells have a variety of checkpoints
that allow mitosis to proceed only when the genetic
material is correctly replicated, thereby maintaining its
intactness throughout replication. Tumor suppressor genes,
such as p53, have a critical role in modulating the
progression of proliferation and in inducing the metabolic
changes necessary for cell survival and correct genome
replication. In normal proliferating cells, the metabolic
program driving cellular growth is apparently regulated
by tumor suppressors in such a way that mitochondrial
oxidative phosphorylation rates are controlled to avoid an
increase in ROS production by high rates of electron
transport chain activity. In tumor cells, which often lose
important tumor suppressor genes, the situation is
different. As demonstrated by Serrano et al. [69], the
acquisition of tumorigenic characteristics by rodent cells
transformed with oncogenic Ras is associated with the
activation of p53 and p16, which is accompanied by cell
cycle arrest and the appearance of a senescence-like
phenotype. When p53 or p16 are inactivated, the cell cycle
progresses normally. These results indicate that, in normal
proliferating cells, the rates of mitochondrial respiration
must be kept regulated and limited to avoid the inhibition
of cell cycle progression by tumor suppressor genes; this
could explain the high rates of aerobic glycolysis and
lactate production in these cells. Interestingly, in cancer
cells with tumor suppressor mutations, oncogenic
activation can be accompanied by increased
mitochondrial respiration without cell cycle inhibition
and senescence. This observation suggests that energy
production in normal proliferating cells is based on
aerobic glycolysis, whereas cancer cells obtain a
significant amount of their energy through increased rates
of mitochondrial oxidative phosphorylation.
In general, any assessment of the relative contri-
bution of glycolysis and the TCA cycle/mitochondrial
respiratory chain in meeting the energy demands of
proliferating cells is a challenging task. Apart from
the metabolic adaptations required to cope with
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proliferation, normal and tumor cells actually show
different metabolic changes, indicating that these two
groups of cells must be analyzed separately. In addition,
the potential influence of the surrounding environment
on the metabolic adaptation of cancer cells and the
existence of short-term mechanisms that enable these
cells to continuously alter the functional status of the
TCA cycle and mitochondrial respiration must be
considered. Since tumor metabolism depends on
nutritional status, tumor cells can continually switch
between oxidative metabolism and fermentation [62, 70].
The relative roles of aerobic glycolysis and
mitochondrial oxidative phosphorylation in proliferating
cells, and especially in cancer cells, are far from
completely understood. However, it is clear that
the metabolic adaptations associated with proliferation in
cancer cells are quite distinct from those displayed
by normal proliferating cells. Future advances in cancer
treatment require a better knowledge of these metabolic
differences.
The molecular basis of the Warburg effect
Oncogenes, tumor suppressors and metabolic
adaptation
The increasing awareness of the importance of
“metabolic transformation” in tumorigenesis and tumor
progression has led to an improvement in our
understanding of the overall metabolic changes that
occur in cancer and normal proliferating cells in
general and the molecular mechanisms that mediate
the Warburg effect in particular.
In terms of their energy requirements and
biomass production, differentiated and undifferentiated
cells are quite distinct. These differences are of course
highly related to the commitment of these cells to
growth and proliferation or, alternatively, to the
maintenance of vital processes that keep them alive and
allow them to execute their biological roles. These
fundamental differences in metabolic needs are reflected
in the distinct regulatory mechanisms that have evolved
to control cellular metabolism in proliferating and non-
proliferating cells [25]. Importantly, the regulatory
mechanisms that allow proliferating and non-proliferating
cells to adapt their metabolism to energy and
biomass production do not work in isolation. Rather, such
regulation is connected to signals that reflect the overall
state of the organism, with the signals being delivered to
the cells through different pathways. In mammals, this
association prevents the proliferation of aberrant cells
when nutrient availability exceeds the levels needed to
support cell division. Indeed, cells do not normally
take up nutrients from their environment unless stimulated
to do so by growth factor signaling pathways.
The connection between metabolic adaptations
and effective signal transduction is a critical event in
cellular homeostasis and a key point in understanding
processes related to the development of cancer. There is
increasing evidence that many of the mutations that
activate oncogenes and inhibit the activity of tumor
suppressors also control the metabolic changes associated
with tumorigenesis [26, 71]. Such alterations may
overcome the dependence on growth factors
through drastic effects on the cell´s ability to capture
nutrients and in the functional status of specific
metabolic pathways that promote cell survival and fuel
cell growth (Fig. 3). Oncogenic mutations can stimulate
the uptake of nutrients, particularly glucose, that meets
or exceeds the energy demands for cell growth and
proliferation [25].
The PI3K/Akt pathway: controlling the metabolic
changes during cell growth
The PI3K/Akt signaling pathway, which acts
downstream of various growth factor receptors and
angiogenesis inducers, plays a critical role in promoting
growth under normoxic and hypoxic conditions [72]. The
importance of the PI3K/Akt pathway in cancer genesis
and progression is demonstrated by the number of
important mutations affecting its transducer molecules.
The amplification of PI3K signaling, the presence of PI3K
mutations and the loss of the tumor suppressor PTEN
(phosphatase and tensin homolog on chromosome 10) are
common in various human tumors. Genetic alterations
upstream and downstream of PI3K signaling molecules,
such as those affecting receptor tyrosine kinases and
PKB/Akt, respectively, are also frequent in human
malignancies [73].
Activation of the PI3K/Akt pathway is probably the
most important event in the regulation of cell metabolism
since it may drive glycolysis and lactate production, the
biosynthesis of important biomolecules and the
suppression of macromolecular degradation in cancer cells
[22]. Additional cellular functions of PKB/Akt are related
to cell cycle progression, survival and angiogenesis, the
latter being a central event for tumor growth and
metastasis. Special attention has been given to signaling
through the kinase mTOR (mammalian target of
rapamycin) which integrates signals from the PI3K/Akt
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pathway and information on the nutrient status to regulate
cell growth and proliferation [72]. The activation of PI3K/
Akt/mTOR signaling enhances many of the metabolic
activities associated with the increase in cellular biomass
in cancer cells, as described below.
PI3K/Akt/mTOR activation enhances the
expression of surface nutrient transporters. Even in
tissues that are not dependent on insulin, PI3K signaling
through PKB/Akt can increase the expression of nutrient
transporters at the cell surface, thereby enhancing the
uptake of glucose, amino acids and other nutrients.
Glucose metabolism is stimulated by an increase in glucose
transporters and HK expression that enhance glucose
entry and metabolism [6].
PKB/Akt increases glycolysis and lactate
production, as well as glutamine metabolism, through
effects on gene expression and enzyme activity. PKB/
Akt activation also contributes to glucose metabolism by
promoting glucose phosphorylation and its retention within
the cell. The PI3K/Akt pathway stimulates HK1 and HK2
activities and promotes the flux of phosphorylated glucose
through the glycolytic pathway stimulated by increased
Santos de Souza/Zenker Justo/Ribeiro de Araújo/Martins Cavagis
Fig. 3. Oncogenes and tumor suppressors drive the metabolic adaptation in tumor cells. Akt, mTOR, Myc, HIF and AMPK
regulate the activities of metabolic pathways associated with the use of glucose, amino acids, glutamine and fatty acids in tumor
cells. AA Transp: amino acid transporter; CIT: citrate; Cyt c: cytochrome c; F1,6BP: fructose 1,6-bisphosphate; F2,6BP: fructose
2,6-bisphosphate; F6P: fructose-6-phosphate; FUM: fumarate; G3P: glyceraldehyde 3-phosphate; G6P: glucose-6-phosphate;
Gln: glutamine; GLU: glucose; Glu: glutamate; GLUT: glucose transporter; LAC: lactate; MAL: malate; OAA: oxaloacetate;
PEP: phosphoenolpyruvate; PYR: pyruvate; Q: coenzyme Q; SCT2 and SLC7A25: glutamine transporters; D-KG: D-ketoglutarate;
1: pyruvate transporter; 2: carnitine palmitoyltransferase; 3: tricarboxylate translocase; 4: glutamine transporter.
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PFK activity. The activation of this signaling pathway
also increases the expression of glycolytic genes [22, 25].
The glycolysis-inducing activities of PKB/Akt also
contribute to apoptosis resistance in cancer cells. PKB/
Akt induces the translocation of HK2 to the outer
mitochondrial membrane where it binds to VDAC. This
event is thought to be associated with the effects of PKB/
Akt on the glycogen synthase kinase 3 (GSK3)-mediated
phosphorylation of VDAC or the phosphorylation of HK2
by PKB/Akt itself [74, 75]. Once associated with VDAC,
HK2 may efficiently couple residual ATP from oxidative
phosphorylation to the initial and rate limiting step of
glycolysis thereby stimulating the glycolytic pathway. In
addition, the binding of HK2 to VDAC may inhibit
mitochondrial membrane permeabilization and the
consequent induction of apoptosis through formation of
the permeability transition pore complex (PTPC) [21, 76].
The increased glycolysis seen in normal proliferating
cells and cancer cells, even during oxygen availability,
reflects the ability of PKB/Akt to activate the hypoxia-
inducible factor 1 (HIF-1) transcription factor complex
through upregulation and stabilization of the HIF-1D
subunit, an event associated with the activation of mTOR
and inhibition of the forkhead transcription factor 3a
(FOXO3a). HIF-1 enhances glycolysis by increasing the
expression of genes encoding glucose transporters (GLUT
1, GLUT 3), glycolytic enzymes (HK1 and 2, PFK1 and
2, aldolase A and C, GAPDH, PGK1, enolase 1, PK-
M2) and LDH-A [77]. HIF-1 also regulates mitochondrial
respiration by increasing the expression of the regulatory
enzyme pyruvate dehydrogenase kinase 1 (PDK1), which
phosphorylates and inactivates the PDC. This event limits
the entry of glycolytic carbon into the TCA cycle
and increases the conversion of pyruvate to lactate [6].
HIF-1 also induces the transcriptional activation of BNIP3,
which encodes a member of the Bcl2 family that, in turn,
triggers selective mitochondrial autophagy [78]. These
activities indicate that HIF-1 is a critical player in the
metabolic shift towards glycolysis in cancer cells.
Constitutive stabilization of the HIF-1D subunit during
normoxia may occur in cancer and appears associated
not only with the ability of PKB/Akt to stabilize this subunit.
Under normal oxygen tension, HIF-1D accumulation is
suppressed by prolyl hydroxylation, which results in
ubiquitination of this protein by the von Hippel-Landau
(VHL) tumor suppressor and its subsequent proteosomal
degradation. ROS inhibit prolyl hydroxylase activity to
promote HIF-1D stabilization, even in the presence of
oxygen. This event contributes to the high rate of aerobic
glycolysis in tumor cells, even in non-hypoxic conditions.
PI3K/Akt activation enhances the biosynthesis
of macromolecules through changes in the expression
of a variety of genes. In numerous cell types, PKB/Akt
promotes the phosphorylation and activation of ACL and
stimulates the expression of lipogenic genes, such as fatty
acid synthase, as well as lipid synthesis in general. PKB/
Akt also inhibits the oxidation of fatty acids through
transcriptional downregulation of carnitine
palmitoyltransferase 1A [21]. Furthermore, PI3K/Akt-
mediated activation of mTOR stimulates an increase in
protein biosynthesis. mTOR coordinates protein synthesis
by regulating amino acid uptake, tRNA charging and
initiation of translation. Signal transduction by mTOR
promotes increased amino acid uptake by upregulating
and maintaining the surface expression of amino acid
transporters. In addition, mTOR induces the initial phase
of protein translation by altering the activity of components
of the translational machinery, such as eIF4F, stimulating
the ribosomal S6 kinase (p70S6K) and increasing the
expression of RNA polymerase III-dependent initiator
methionine tRNA [26].
PI3K/Akt suppresses macromolecular
degradation in cancer cells. Autophagy is a dynamic
process involving the bulk degradation of cytoplasmic
organelles and proteins. Autophagy is essential for the
maintenance of cellular and metabolic homeostasis, mainly
through the production of amino acids, ATP-generating
substrates and continuous removal of either functionally
redundant or aberrant intracellular structures [79]. Tor/
mTOR plays a central role in regulating autophagy from
yeast to mammalian cells. Through mTOR, PI3K/Akt
inhibits catabolic reactions stimulated by autophagy,
predominantly by activating the downstream molecule
p70S6K.
The LKB1/AMPK pathway: a tumor suppressor
axis linking metabolic status and cell growth
The AMP-activated protein kinase (AMPK) is a
sensor of cellular energy status and is activated
under stress conditions, such as hypoxia and nutrient
deprivation, in which intracellular ATP levels decrease
while the AMP concentration increases. In this
situation, AMPK is phosphorylated by its major upstream
kinase, liver kinase B1 (LKB1), and, as a consequence,
cell growth is halted and ATP-consuming processes are
attenuated [80]. This action is consistent with the role of
LKB1 as a tumor suppressor. LKB1 gene mutations
were originally described in Peutz-Jeghers syndrome,
an inherited cancer disorder [81], although somatic
LKB1 mutations also occur in non-small cell lung cancers
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[82] and cervical carcinomas [83, 84]. LKB1 deletion is
associated with hyperplasia and tumorigenesis in some
tissues [85].
The mTOR pathway is a key cancer-related target
of the LKB1/AMPK pathway. Under energy stress,
activated AMPK can directly phosphorylate two important
components of the mTOR complex 1 (mTORC1),
namely, the tuberous sclerosis complex 2 (TSC2) tumor
suppressor and the scaffold protein raptor. As a
consequence, mTORC1 and its downstream effects on
protein translation and cell growth are inhibited [80].
In contrast to PKB/Akt signaling, AMPK phosphorylates
and activates the transcription factor FOXO3a and
stimulates p53-induced apoptosis and mTOR inhibition;
these observations indicate opposing effects of
PI3K/Akt and LKB1/AMPK on cell growth and
metabolism [86].
Of importance is the central role of AMPK in
regulating glucose and lipid metabolism as a function of
the energy and nutritional status of the cell. Activation of
AMPK directly phosphorylates and inhibits acetyl-CoA
carboxylase and HMG-CoA reductase, thereby reducing
fatty acid and cholesterol synthesis [87]. AMPK is also
associated with the downregulation of glycolysis through
the phosphorylation of PFK2. The demonstration
that deletion of the PFKFB3 gene (an inducible PFK2
isoform) inhibited the transformation of mouse lung
fibroblasts and the tumor growth suppressing activity of
PFK2 inhibitors in vivo [88, 89] led to the proposal that
pharmacological inhibition of this enzyme may suppress
glycolysis and tumor growth [90]. In addition, Shackelford
et al. [91] have recently described increased levels of
HIF-1D, GLUT1 and HK in LKB1- and AMPK-deficient
mouse embryonic fibroblasts, and their downregulation
by rapamycin. Similar results were found in patients
with Peutz-Jeghers syndrome, indicating a potential
role for HIF-1D as a metabolic mediator of LKB1
deficiency.
Specific mTORC1 inhibitors have been developed
for clinical use, and these drugs have been anticipated to
provide efficient treatment for cancer and hamartoma
syndromes [92]. In this scenario, the drug metformin, an
activator of AMPK commonly used to treat patients with
type 2 diabetes, has been identified as a promising drug
for the treatment of cancer. Indeed, studies with cancer
patients presenting diabetes demonstrated that those
treated with metformin were more likely to be cancer
free over eight years than those on other treatment
regimens [93]. Metformin is currently being tested in phase
I and phase II clinical trials.
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Myc family genes: metabolic adaptations to cell
cycle entry and genome duplication
To proliferate, cells must achieve two main goals,
namely, increase their biomass (cell growth) and duplicate
their genetic material. Accordingly, proliferation requires
metabolic adaptations to increase the biosynthesis of
molecules such as lipids and proteins and sustain the
massive nucleotide biosynthesis required for genome
duplication. While the first of these demands on cellular
metabolism is regulated by growth factor signaling
pathways, the metabolic changes required for genome
duplication depend on the activation of genes that modulate
entry into the cell cycle in response to proliferative signals.
The Myc family of genes (c-Myc, L-Myc, S-Myc
and N-Myc) encodes transcription factors that regulate
a variety of cellular processes, including cell growth and
proliferation, cell cycle progression, energy metabolism,
differentiation, apoptosis and cell motility. In most human
cancers, Myc activity is altered by single nucleotide
polymorphisms, chromosomal translocations and gene
amplification. Enhanced Myc expression is seen in 70%
of all human cancers and the suppression of its expression
may lead to tumor regression [94-96].
The Myc genes link altered cellular metabolism to
tumorigenesis through a variety of activities that reinforce
the metabolic changes induced by growth factors.
Additionally, Myc exerts a key role in organelle biogenesis,
which is required for energy production, biosynthesis and
cell growth. Myc also stimulates entry into the cell cycle
and the DNA duplication required for cellular division.
Myc was recently demonstrated to have a direct role in
controlling DNA replication via a transcription-
independent mechanism based on its interaction with the
pre-replicative complex during DNA synthesis [97]. The
control of protein expression by Myc is mediated through
effects on mRNA translation and the expression of a
number of translation initiation factors [98].
Myc cooperates with HIF-1 to regulate genes
involved in glucose and glutamine metabolism. Like
the PI3K/Akt pathway, Myc is a strong inducer of
enzymes associated with glucose metabolism. Most of
the glycolytic and glucose transporter genes, such as
LDH-A, GLUT1, HK2, PFK, hexosephosphate isomerase
(HPI), GAPDH, PGK and enolase 1, are transcriptionally
activated by Myc [8]. HIF-1 also directly regulates
the transcription of many genes regulated by Myc,
indicating the existence of functional interplay between
Myc and HIF-1; this interplay could contribute to the
Warburg effect, even under adequate oxygen tension [67,
99, 100].
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The effects of Myc on glutaminolysis involve the
upregulation of glutamine transporter genes (SCT2 and
SLC7A25), which are direct targets of Myc, and an
increase in glutaminase protein levels mediated by post-
trancriptional regulatory mechanisms [67, 68].
Glutaminase is responsible for the conversion of glutamine
to glutamate which is in turn converted to D-ketoglutarate
and finally to malate in the TCA cycle. Malate is then
transported out of the mitochondria to the cytoplasm,
where it is converted to pyruvate by the malic enzyme,
with the concomitant production of NADPH from
NADP+. Pyruvate is then converted to lactate by LDH-
A. In addition to its role in modulating the increase in cell
biomass and entry into the cell cycle, Myc also elevates
the levels of intracellular NADPH, thereby supporting
anabolic synthesis and contributing to the intactness of
the replicating genome in proliferating cells. Recent work
suggests that cancer cells select enzymatic mutations,
such as those affecting Myc and isocitrate dehydrogenase
1 (IDH1), that influence cytoplasmic NADPH production
during transformation [101].
Besides promoting glucose metabolism through
aerobic glycolysis and stimulating the conversion of
pyruvate into lactate, Myc can also stimulate pyruvate
synthesis through glutaminolysis. During this process, the
TCA cycle is supplied with D-ketoglutarate to yield
precursors for the synthesis of biological molecules. In
addition, D-ketoglutarate can be used by the TCA cycle
to generate ATP and reduced coenzymes. In this way,
glutamine stimulates mitochondrial respiration in tumor
cells through glutaminolysis [62, 63]. Myc can also
stimulate oxidative phosphorylation, in agreement with its
role as an inducer of mitochondrial biogenesis and of genes
related to mitochondrial function.
Myc regulates genes involved in the biogenesis
of ribosomes and mitochondria. Organelle synthesis is
a key function exerted by Myc since proliferating cells
require an increase in the number of organelles to provide
daughter cells with the machinery necessary for survival
and growth. Furthermore, an increase in organelle number
per se is advantageous for proliferation as it increases
the synthesis of biomolecules and energy production.
Myc transcriptional activity is associated with
enhanced mitochondrial mass and function. This event is
related to the ability of Myc to upregulate genes important
for mitochondrial biogenesis, mtDNA transcription and
oxidative phosphorylation [102, 103]. The fact that the
Myc proto-oncogene stimulates glucose uptake and
glycolysis while at the same time promoting mitochondrial
respiration (indirectly through an increase in mitochondrial
number and directly through stimulation of oxidative
phosphorylation) is consistent with an important role for
ATP production by mitochondria in proliferating cells and
lends further credibility to the hypothesis that the TCA
cycle and oxidative phosphorylation are essential here.
However, Myc also induces the expression of PDK1 and
avoids pyruvate conversion to acetyl-CoA. As a
consequence, pyruvate is withdrawn from oxidative
mitochondrial metabolic pathways, an apparent paradox,
considering the positive influence of Myc on mitochondrial
proliferation and the stimulation of oxidative
phosphorylation following expression of the proto-
oncogene. In this context, the ability of Myc to promote
glutaminolysis (see previous section) means that Myc can
induce glutamine oxidation concurrently with aerobic
glycolysis.
In addition to mitochondrial biogenesis, Myc is
implicated in the synthesis of ribosomes and the stimulation
of protein synthesis. The effects of Myc on ribosome
biogenesis are related to the ability of this transcription
factor to stimulate transcription by RNA polymerases I
(for rRNA transcription) and III (for tRNA and small
RNA transcription), in addition to RNA Pol II [67].
Moreover, Myc controls the expression of multiple
components of the protein synthesis machinery, including
ribosomal proteins, tRNA levels and key factors involved
in translation initiation and elongation such as eIF4F
subunits eIF4AI and eIF4GI [104, 105].
Myc induces cell cycle progression. Studies over
the past 25 years have demonstrated the ability of Myc
to suppress or stimulate the expression of various targets
associated with the promotion or suppression of cell cycle
progression. Among its effects, Myc can abrogate the
transcription of checkpoint genes such as GADD45 and
GAD153, p21 and p15, and inhibit the function of cyclin-
dependent kinase (CDK) inhibitors. Additionally, Myc
promotes cell cycle progression by stimulating cyclin D1,
cyclin D2, cyclin E1, cyclin A2, CDK4, CDC25A and
E2F2 [106]. As a result of Myc expression, G1 is often
shortened as cells enter the cell cycle, and Myc is essential
for G0/G1 to S phase progression. Myc expression in G1
facilitates cell entry into S, partly by activating the
expression of cyclins and CDK4 [107].
The tumor suppressor gene p53
The p53 protein, encoded by the tumor suppressor
gene p53, is a vital transcription factor that mediates
cellular adaptation to a variety of stress conditions,
including hypoxia, DNA damage and oxidative stress.
Indeed, once stabilized and activated, p53 stimulates the
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expression of genes that induce cell cycle arrest,
senescence and apoptosis. p53 also regulates the cellular
potential for angiogenesis and, importantly, can coordinate
the function of metabolic pathways by triggering stress-
induced transcriptional programs in order to maintain
energy homeostasis. In this context, p53 mediates
metabolic adaptation through activation of AMPK by
energy-related stress signals. The activation of p53 by
metabolic stress is associated with its phosphorylation that
is directly mediated through AMPK. Once activated, p53
alters the function of specific catabolic pathways and
stimulates macroautophagy, in addition to other actions.
p53-induced expression of the gene TIGAR (TP53-
induced glycolysis and apoptosis regulator) leads to a
decrease in fructose 2,6-bisphosphate. Since fructose 2,6-
bisphosphate is an allosteric activator of PFK-1, glycolysis
is consequently reduced, thereby contributing to the
Crabtree effect through diversion of the glucose flux to
the pentose phosphate pathway and a reduction in
mitochondrial oxidative phosphorylation [108]. In addition
to its effects on TIGAR expression, p53 also increases
mitochondrial respiration by stimulating the expression of
SCO2 (synthesis of cytochrome oxidase 2), which is
required for the assembly of cytochrome c oxidase [22].
The activation of p53 is associated with the
stimulation of intracellular catabolic processes, including
macroautophagy. Through upregulation of the damage-
regulated autophagy modulator (DRAM) gene, nuclear
p53 induces the expression of a lysosomal protein that
stimulates the degradation of macromolecules during
autophagy. The effect of p53 activation on autophagy is
dualistic and dependent upon the subcellular localization
of this transcription factor. Indeed, p53 activities are not
limited to its action as a transcription factor and many
other p53-related effects are associated with non-
transcriptional actions. Thus, p53 can function as a nuclear
transcription factor in the transactivation of proautophagic
genes, while cytoplasmic p53 can operate in mitochondria
to promote cell death and repress autophagy via poorly
characterized mechanisms [109]. Finally, p53 contributes
to catabolic processes by enhancing the E-oxidation of
fatty acids through the action of carnitine palmitoyl-
transferase, an enzyme that regulates mitochondrial fatty
acid import [110].
Another important function of p53 is related to its
ability to inhibit angiogenesis by inducing the expression
of anti-angiogenic factors. p53 protein limits angiogenesis
by at least three mechanisms: (1) interfering with central
regulators of hypoxia that mediate angiogenesis, (2)
inhibiting the production of pro-angiogenic factors and
(3) directly increasing the production of endogenous
angiogenesis inhibitors. The combination of these effects
allows p53 to efficiently shut down the angiogenic potential
of cancer cells [111].
The functional status of p53 in tumor cells has always
been considered an important indicator of cancer prognosis
since the actions of this protein are strictly linked to the
control of death and survival. The recent findings showing
the consequences of p53 activation in metabolic
adaptations to stress reinforce the critical role of this
protein in cancer outcomes.
Metabolic therapies for cancer
Since the discovery of the Warburg effect, our
knowledge of the metabolic specificities of highly
proliferating normal cells and cancer cells has grown
considerably. However, despite our incomplete
understanding of cancer cell metabolism, several trials in
vitro and in vivo have attempted to exploit our current
knowledge to improve the treatment of cancer in
strategies now referred to as “metabolic therapies” [10,
13]. Currently, several potential drugs that target metabolic
pathways are being developed and are undergoing clinical
trials [112].
The use of metabolic therapies has some advantages
over other approaches. One of the driving ideas is that
such therapies offer enhanced specificity since tumor cells
appear to be more sensitive to metabolic inhibitors than
their normal counterparts [13, 47]. Moreover, metabolic
therapy may be applicable to a wide spectrum of tumor
types since, regardless of the specific signaling
dysfunctions, the activation of different oncogenes or loss
of tumor suppressors has been associated with similar
effects in tumor metabolic adaptations. Recent work has
demonstrated the role of glycolysis in regulating P-gp
expression, with higher glycolytic rates being related to
increased P-gp expression and the emergence of the MDR
phenotype in cancer cells [36]. Inhibition of the glycolytic
pathway may therefore represent a potentially useful
strategy for overcoming MDR in cancer therapy.
Glycolytic rates have been correlated with the
degree of tumor malignancy such that faster rates are
associated with de-differentiated and fast growing tumors
rather than with slow growing tumors or normal cells. In
addition, high glycolysis in tumor cells has been related to
increased resistance to chemotherapy and radiotherapy
[8]. Based on these findings, glycolysis-inhibiting drugs
have been used alone or in combination with traditional
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anticancer drugs to reduce tumor progression and/or
enhance the efficacy of current anticancer therapies. A
number of glycolysis-inhibiting drugs have successfully
impaired cell growth in vitro [12, 113], although some of
them are not very efficient in causing cell cycle arrest
and/or death in certain types of cancer. A possible
explanation for this is that not all tumor cells have a
glycolysis-dependent metabolic program. As previously
stated, many tumor cells are dependent upon the proper
functioning of mitochondrial oxidative respiration, even
though they have high glycolytic rates. In addition, even
tumor cells that are highly dependent on glycolysis may
shift between aerobic and fermentative metabolism,
depending on the environmental conditions [114]. It is
therefore conceivable that glycolysis-inhibiting drugs may
only be useful in tumor cells that have dysfunctional
mitochondrial oxidative pathways and/or oxidative
phosphorylation, or those that, despite the absence of such
dysfunctions, still have an absolute dependence on high
rates of glycolysis. In contrast to the limitations associated
with the use of glycolysis-inhibiting drugs as monotherapy,
promising results have been obtained with the use of 2-
deoxyglucose, 3-bromo-pyruvate, lonidamine and other
compounds in combination with radiotherapy or
anticancer drugs commonly used in chemotherapy.
Indeed, several studies have suggested that the use of
glycolysis-inhibiting drugs increases the sensitivity towards
anticancer drugs [9, 115-118], and some of these drugs
are being tested in phase II and III clinical trials in
combination with other agents [119-123].
Drugs that inhibit oxidative phosphorylation, such as
rotenone, rhodamines and oligomycin, have also been
tested for their ability to impair the proliferation of tumor
cells that have functionally normal mitochondria. However,
two main problems have appeared with this strategy. The
first problem is the apparent inefficiency of such drugs to
significantly impair tumor cell growth, at least in vitro
[124]. The ability of tumor cells to increase their glycolytic
rates and reduce dependency on mitochondrial metabolic
pathways may be potentiated when they are exposed to
a glucose-rich environment during experiments in vitro;
this question deserves further investigation. The second
problem is the need for safer oxidative phosphorylation-
inhibiting drugs than those currently available.
The results obtained with glycolysis- or oxidative
phosphorylation-inhibiting drugs support the notion that
tumors are highly adaptable in their metabolism and can
adjust their metabolism to suit changing environmental
conditions. This adaptability suggests that tumor cell
metabolism cannot be suppressed by using glycolysis or
oxidative phosphorylation inhibitors alone but, rather, that
a combination of these compounds or their association
with traditional chemotherapeutic drugs may be a potential
strategy.
In addition to the use of inhibitors of glycolysis and
oxidative phosphorylation, metabolic therapies have also
targeted other aspects of tumor metabolism. The inhibition
of glucose transport by GLUT-inhibitors has yielded
positive results in vitro and in vivo [125, 126]. Although
none of these drugs are currently in clinical use, GLUT
transporters have been considered more adequate
therapeutic targets than the direct inhibition of glycolysis
[127]. In addition, given the advantages of lactate
production and release to cancer cells, the suppression
of membrane lactate transport between cancer cells
through the inhibition of MCT proteins may be another
potentially useful anticancer therapy. MCT proteins
located in the plasma membrane use facilitated diffusion
to mediate the symport of monocarboxylate (pyruvate,
lactate, aromatic amino acids and ketone bodies) with a
proton, as well as the exchange of metabolic products
between cells and organs in non-pathological conditions
[10]. MCT based-studies have shown that some isoforms
of these transporters, such as MCT1 and MCT2, are
overexpressed in cancer cells, which suggests a need for
these cells to maintain low levels of intracellular lactate.
Indeed, as discussed above, the function of MCT proteins
in tumor cells is related to the regulation of lactate
availability and pH balance inside and outside the cells.
These events are important for maintaining the lactate
trade and integrated metabolism established within the
tumor mass and for conferring greater mobility and
angiogenic potential to cancer cells [128]. Current
experimental evidence indicates reduced viability and
diminished invasiveness of cancer cells in which MCT
expression or function is attenuated [7, 43]. Although no
MCT inhibitors are currently undergoing clinical trials,
the suppression of lactate production has been highlighted
as a potential strategy to combat cancer cells.
Concluding remarks
Since the original pioneering studies of Otto Warburg,
research on tumor cell metabolism has proven to be a
promising field for the development of novel strategies to
combat cancer growth, survival, invasiveness and
resistance. Recent work has demonstrated the central
role played by metabolic transformation in cancer genesis,
survival and progression, and has highlighted the potential
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use of metabolic alterations as targets for anticancer drugs.
However, despite the advances in our knowledge of
cancer metabolism, there are still no answers to key
aspects of the metabolic alterations associated with the
onset of cancer, such as the exact role of the TCA cycle
in energy production in cancer cells. Defining the
metabolic differences between highly proliferating cells
and cancer cells is pivotal for understanding cancer
metabolism and the development of more selective
antitumor therapies. Detailed analysis of the functional
status of metabolic pathways in tumors has revealed a
variety of metabolic conditions within the tumor and the
adaptability of tumor metabolism. A better understanding
of this heterogeneity in cancer metabolism, coupled to
the development of combined therapies that target
different metabolic pathways to counteract tumor
metabolic plasticity, seems to be essential for modulating
cancer metabolism and improving the efficacy of current
therapies.
Despite the challenges in understanding cancer cell
metabolism (heterogeneity, plasticity etc.) some success
has been achieved using metabolic therapies. This success
is apparently related to the increased sensitivity of cancer
cells to metabolic anticancer drugs and to the fact that
this approach is independent of the specific signaling or
epigenetic dysfunctions associated with the origin of
cancer.
Alterations in cancer cell metabolism are intricately
linked to the principal hallmarks of cancer. Inhibition of
the processes and enzymes that participate in metabolic
reprogramming may have a dramatic effect on tumors
by reverting the neoplastic phenotype, stopping growth,
inducing apoptosis and/or blocking angiogenesis and
invasion. Clearly, understanding tumor metabolism is a
challenging task but, at the same time, provides a promising
target for improving traditional anticancer therapies.
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